Novartis, Pfizer to co-market Exforge in October

Novartis Korea and Pfizer Korea said on September 6 that they will begin the co-marketing of Exforge, a combined formulation of amlodipine, a dihydropyridine calcium-channel blocker, and valsartan, an angiotensin II receptor antagonist in October through mutual agreement on August 30.

This oral prescription drug is known to be most effective in patients whose blood pressure is not sufficient...